Tarsus Pharmaceuticals, Inc. (TARS) Income Statement

The reported growth rate has moderated from triple-digit levels in 2025 to the low-to-mid 60 percent range, which suggests the early launch surge is maturing. Growth appears driven primarily by volume expansion as prescriber adoption broadens, though the reported data does not separate price from volume, so durability remains uncertain. Investors should monitor whether sequential growth holds as the addressable patient pool becomes increasingly penetrated.

The consistently high gross margin is characteristic of a small-molecule therapeutic with minimal marginal production cost, which supports the strength of the underlying franchise. The gap between gross and operating margin reflects a large fixed commercial and R&D base that has not yet been spread across sufficient revenue. Whether operating margin turns positive will depend on whether revenue growth outpaces the continued expansion of SG&A and R&D spending.

Operating income narrowed materially across most of the period, implying that gross profit growth has at times exceeded operating expense growth. The 2026Q3 figure, however, is a sharp outlier that does not reconcile with the stated SG&A and R&D levels, suggesting a possible one-time charge or data issue that analysts should verify. Until the quarterly operating trajectory is confirmed, the degree of genuine operating leverage remains an open question.